Newly Available Synchrotron X-Ray Sources Reduce Competition for Access to Beamlines | GenomeWeb

As structural biology companies race ahead to obtain x-ray crystallography structures of promising drug targets, the biggest hurdle has traditionally been getting access to tunable x-ray sources at synchrotrons.

“The capacity is there,” said Lance Stewart, CEO of Emerald BioStructures, a subsidiary of MediChem Life Sciences. “But the timing with which you can get access to this capacity is not very efficient.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.